• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Regeneron's high-dose Eylea shows staying power as company awaits FDA decision

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 10, 2023 at 09:52: PM
via As Regeneron anxiously awaits an FDA decision on a high-dose version of Eylea (aflibercept), the company has continually referred to its durability compared to that of Roche’s upstart Vabysmos—which has taken the macular degeneration (AMD) market by storm since receiving approval 19 months ago.

article source
 




Top Bottom
Back
Quote